診療科・部門紹介
血液・腫瘍内科
診療内容
亀田総合病院の血液・腫瘍内科は1990年より開設されました。この間房総半島における白血病、悪性リンパ腫や骨髄腫の治療の中心施設として多くの患者さまの治療に当たってきております。現在では常時80名前後の患者さまが入院されており本邦でももっとも大きな血液疾患の治療施設の一つとなっております。さらに当科は日本血液学会の専門医研修施設、日本骨髄バンク認定非血縁者間骨髄移植および骨髄採取指定施設、日本臍血バンク認定臍帯血移植施設として千葉県の血液疾患治療の中心的な施設となっており近年では房総半島、千葉県だけでなく都内やそれ以外の地方からの患者さまも増加してきています。
病棟での診療はシニアレジデント以上のスタッフ6名に加えジュニアレジデント1〜2名の医師で患者さまの治療を担当しております。特に骨髄移植、末梢血幹細胞移植などを用いた治療では、既に多くの経験と実績を上げております。骨髄移植は1990年から開始しておりこれまでに同種幹細胞移植の試行数は400例を超しております。最近の3年間の移植数は年間15−25例前後となっています。また悪性リンパ腫や多発性骨髄腫に対する自家末梢血幹細胞移植も積極的に行っており、これまでのべ200例を超える自家移植が行われております。これらを行う施設としては以前からのKタワー9階に無菌室16床を含む36床、また新しく出来たAタワー8階に個室2棟を含む42床の計78床が稼働しています。
亀田総合病院では、どの患者さまにも最新鋭の機器による最新の治療を行えるように努力しております。たとえば画像診断の分野では、どの科においてもPETをはじめ、MRI、CTなどによる画像診断検査が緊急な場合を含めて必要に応じて行える体勢がとられております。この事は急変する病態が多い血液悪性腫瘍の患者さまにとってはきわめて重要なであり、高度医療を行う上で必須であると考えられます。
臨床検査センターにはFACSが導入され、30種類を越えるモノクローナル抗体を用いた白血病・リンパ腫, 骨髄腫の表面抗原の解析診断がルーチンに行われ、様々の造血器悪性腫瘍のモノクローナル抗体による診断が迅速に行える体制がとられております。特に骨髄腫の治療経過を判定する上での骨髄微少残存病変(MRD)の検索は8-10カラーフロサイトメトリーを用いてルーチンに行われ国内をリードしています。また、再生不良性貧血、骨髄異形性症候群ではPNH赤血球の高感度測定法による測定をおこない、免疫抑制療法が有効と思われる再不貧やMDSのサブグループの診断が行われております。特にリンパ腫の診断では血液検査室、病理部門との協力によりリンパ節生検が行われてから3日以内で表面マーカの解析とH-E標本ができる体制がとられ急速に進行する造血器悪性腫瘍にたいして的確な診断と治療が行われる体制をとっています。病理診断に関しても血液病理専門医が毎月来院しスタッフと一緒にリンパ節の病理を診ることで病理診断をより確かなものとしています。またFISHやPCRを用いての遺伝子診断も多くの疾患でルーチンに行われ正確な診断を基に国内的にはもちろん国際的にも最新の診断と治療が行われています。
造血幹細胞移植は当科でも力をいれている分野の一つですが、先に述べましたように年間30例前後の臍帯血、同種および自家末梢血幹細胞、同種骨髄移植をおこなっています。当科の特徴としては地域性を反映して高齢者での移植が多いことです。特に骨髄腫では70才以上の患者さんに対しても､可能な患者さんには自家末梢血幹細胞移植を積極的に行い良好な成績が得られております。また、白血病や悪性度の高いリンパ腫に対してわれわれは60才以上の患者さまに対しても同種幹細胞移植を積極的におこなっており、60才以下の患者さまと遜色ない良好な成績が上げられています。またいくつもの臓器障害を有したり、治療抵抗性であったりする難治例での移植にも積極的に取り組んでいますがその治療成績はまだ十分とは言いがたく、今後はこれらの患者さまの治療成績の向上が課題と思われます。これらの重症の患者さまの移植を安全かつ効果的に行うために、GVH病のコントロールに必要なサイクロスポリン、タクロリムスの血中濃度の緊急測定、真菌感染におけるアスペルギルス抗原の院内測定といった新しい治療に必要な検査のサポートが受けられる体制がとられております。輸血部では血液細胞の分離保存専用のクリーンベンチを始め、血液照射装置、血液成分分離装置、-135℃の超低温冷蔵庫2台などが備えられ、造血細胞のプロセッシングと保存が行われており最先端の血液疾患の診断と治療に対応できます。放射線部ではライナックが備えられ、CTやMRI、PETなどの最先端の診断機械なども多く備えられています。
学会活動としては、日本血液学会、リンパ網内系学会、日本造血幹細胞学会、American Society of Blood and Marrow Transplantation、European Haematology Association, American Society of Hematologyなどの国内外の学会に積極的に参加・発表しております。当科より発信された主な業績としては、ミカファンギンのよるトリコスポロン症のbreak through （Clin Infec Dis. 2006）血管内大細胞型B細胞リンパ腫の診断とランダム皮膚生検の有効性（Mayo Clin Proc. 2007）, 幹細胞移植患者やリツキシマブ投与患者におけるＢ型肝炎の再活性化(Cancer. 2010)、血管内リンパ腫とNeurolymphomatosis との関連 (Cancer 2011), イマチニブ服用患者におけるα2プラスミン活性の低下と粘膜出血 (Thromb Haemost 2009)、腎不全をともなった骨髄腫の患者の腎機能回復と尿中アルブミンとの関連（Blood Cancer J. 2014）, MDSや骨髄腫におけるmultidetector CT による予後予測(Leukemia. 2018, Blood Advances 2018) , 骨髄腫患者に対するdaratumumab投与とregulatory T-cell (Haematologica 2019), ランダム皮膚生検の感度と特異度(Br J Dermatol. 2019, Blood 2019, BJH 2019) など多岐にわたっています。最近では、血液疾患におけるコロナワクチン接種後の抗体価について多くの研究成果をトップジャーナルに報告しています（BJH 2021, BJH 2022, HemaSphere 2023)。その他にも当院の特徴である電子カルテシステムを利用した質の高い臨床研究を立案し、積極的に行うことで今後とも当院から有用な情報を世界に発信できるように努力してゆきたいと考えております。
このようにすぐれた設備、医療環境のもとで私たちは国の内外をリードする創造的な血液・腫瘍内科を目標に、最新の知見に基づいた診断や治療をおこない、患者さまやそのご家族に満足して頂ける医療を目指して共に今後も努力してゆきたいと考えております。
論文業績 (過去5年) （共同研究は*）
- 2024年
-
1) Ikeda D, Oura M, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K. Efficacy of darinaparsin for EBV-associated B-cell lymphoma in a heavily treated elderly patient with angioimmunoblastic T-cell lymphoma: a case report. Leuk Lymphoma (IF: 3.28; Q3). 2024 Jan;65(1):132-135. doi: 10.1080/10428194.2023.2265001. Epub 2024 Jan 10. PMID: 37794793 No abstract available.
2) Ikeda D, Terao T, Oura M, Uehara A, Tabata R, Narita K, Takeuchi M, Machida Y, Matsue K. Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma. Blood Adv (IF: 6.69; Q1). 2024 Jan 9;8(1):37-46. doi: 10.1182/bloodadvances. 2023011890. PMID: 38150271 Free PMC article.
*3) Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Maeda T, Yoshida T, Mori I, Shinozaki T, Iida S. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Ann Hematol (IF: 3.67; Q2). 2024 Feb;103(2):475-488. doi: 10.1007/s00277-023-05428-7. Epub 2023 Sep 11.PMID: 37695378 Free PMC article.
*4) Suma S, Suehara Y, Fujisawa M, Abe Y, Hattori K, Makishima K, Sakamoto T, Sawa A, Bando H, Kaji D, Sugio T, Kato K, Akashi K, Matsue K, Carreras J, Nakamura N, Suzuki A, Suzuki Y, Ito K, Shiiba H, Chiba S, Sakata-Yanagimoto M. Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution. Leukemia (IF: 11.53; Q1). 2024 Feb;38(2):340-350. doi: 10.1038/s41375-023-02093-7. Epub 2023 Nov 27.PMID: 38012392 Free PMC article.
*5) Morita K, Karashima S, Terao T, Yoshida K, Yamashita T, Yoroidaka T, Tanabe M, Imi T, Zaimoku Y, Yoshida A, Maruyama H, Iwaki N, Aoki G, Kotani T, Murata R, Miyamoto T, Machida Y, Matsue K. , Nambo H, Takamatsu H.J. 3D CNN-based Deep Learning Model-based Explanatory Prognostication in Patients with Multiple Myeloma using Whole-body MRI. Med Syst (IF: 4.46; Q2). 2024 Mar 8;48(1):30. doi: 10.1007/s10916-024-02040-8.PMID: 38456950
6) Ikeda D, Oura M, Uehara A, Tabata R, Narita K, Takeuchi M, Machida Y, Matsue K. Prognostic relevance of tumor-infiltrating CD4+ cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma. Haematologica (IF: 9.94; Q1). 2024 Sep 1;109(9):2822-2832. doi: 10.3324/haematol.2024.285038.PMID: 38572548
*7) Izutsu K, Kato H, Sekiguchi N, Fujisaki T, Kawakita T, Obara N, Matsue K, Nishimoto M, Hatayama T, Inagaki M, Fujikawa E. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia. Int J Hematol (IF: 2.49; Q3). 2024 Jul;120(1):80-90. doi: 10.1007/s12185-024-03761-9. Epub 2024 Apr 10. PMID: 3859798
8) Ikeda D, Oura M, Uehara A, Tabata R, Narita K, Takeuchi M, Machida Y, Matsue K. Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study.
Blood Adv (IF: 6.69; Q1). 2024 Apr 23;8(8):1893-1897. doi: 10.1182/bloodadvances.2023012165. PMID: 38359408 Free PMC article. No abstract available.9) Uesugi Y, Ikeda D, Fukumoto A, Tabata R, Miura D, Narita K, Takeuchi M, Matsue K. Use of the Second Revision of the International Staging System for prognostic stratification of multiple myeloma patients in real-world clinical practice and the importance of sub-groups, including age.
Haematologica (IF: 9.94; Q1). 2024 May 1;109(5):1593-1597. doi: 10.3324/haematol.2023.284173. PMID: 38031801 Free PMC article. No abstract available.*10) Sakuma I, Ishibashi R, Matsue K, Vatner DF, Nakamura Y, Yokote K, Tanaka T. Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man. Lancet (IF: 79.32; Q1). 2024 Jun 1;403(10442):e33. doi: 10.1016/S0140-6736(24)00974-7. PMID: 38823995 No abstract available.
11) Ikeda D, Isezaki T, Narita K, Yuyama S, Oura M, Uehara A, Tabata R, Takeuchi M, Matsue K. Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies.
Cancer Chemother Pharmacol (IF: 3.33; Q3). 2024 Jun 21. doi: 10.1007/s00280-024-04687-z. Online ahead of print. PMID: 38902559*12) Narita K, Okamoto A, Iba S, Tabata R, Ikeda D, Oura M, Uehara A, Takeuchi M, Takeuchi K, Tomita A, Matsue K. Analysis of the clinical features and outcomes of relapsed intravascular large B-cell lymphoma: a single center study.. Leuk Lymphoma (IF: 3.28; Q3). 2024 Sep 3:1-4. doi: 10.1080/10428194.2024.2389213. Online ahead of print. PMID: 39225391
13) Tabata R, Matsue K. ALK-positive anaplastic large cell lymphoma, Hodgkin-like pattern with unexplained fever. Blood (IF: 22.11; Q1). 2024 Sep 26;144(13):1460. doi: 10.1182/blood.2024024998.PMID: 39325483
14) Ikeda D, Aikawa S, Misono C, Oura M, Fujii F, Sakuma H, Toho M, Uehara A, Tabata R, Narita K, Takeuchi M, Watari T, Otsuka Y, Matsue K. Soluble B-cell maturation antigen levels for disease monitoring in ologo- and non-secretary multiple myeloma. Blood (IF: 22.11; Q1). 2024 Oct 23:blood.2024026028. doi: 10.1182/blood.2024026028. Online ahead of print.PMID: 39441915
- 2023年
-
1)* Yoroidaka T, Yamashita T, Murata R, Yoshihara K, Yoshihara S, Ueda M, Nakao S, Matsue K, Takamatsu H. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone. Anticancer Res (IF: 2.48; Q4). 2023 Jan;43(1):157-165. doi: 10.21873/anticanres.16145.PMID: 36585165
2)* Shibata S, Arai Y, Kondo T, Mizuno S, Harada K, Miyakoshi S, Uchida N, Maruyama Y, Eto T, Katsuoka Y, Matsue K, Nishiwaki K, Takada S, Doki N, Itoh M, Nagafuji K, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Yanada M. Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation. Transplant Cell Ther (Report missing IFs). 2023 Feb 14:S2666-6367(23)01072-2. doi: 10.1016/j.jtct.2023.02.004. Online ahead of print.PMID: 36796517
3) Fukumoto A, Sugihara S, Seki K, Takeuchi M, Suzuki T, Kosei M. Kidney involvement of chronic active Epstein-Barr virus infection. EJHaem (Report missing IFs). 2023 Jan 20;4(1):278-279. doi: 10.1002/jha2.641. eCollection 2023 Feb.PMID: 36819161
4) Tsushima T, Terao T, Narita K, Fukumoto A, Ikeda D, Kamura Y, Kuzume A, Tabata R, Miura D, Takeuchi M, Matsue K. Clinical Characteristics and Outcomes of Cyclin D1-Positive AL Amyloidosis. Am J Clin Pathol (IF: 2.49; Q3). 2023 Mar 20:aqad013. doi: 10.1093/ajcp/aqad013. Online ahead of print. PMID: 36940250
5) Narita K, Ikeda D, Seki M, Fukumoto A, Tabata R, Yuka Uesugi, Miura D, Takeuchi M, Doi M, Umezawa U, Otsuka Y, Matsue K. Prevalence and clinical outcome of Omicron breakthrough infection in patients with hematologic disease: a prospective observational cohort study. HemaSphere 2023 Jun 6;7(6):e905.
6) Fukumoto A, Narita N, Ikeda D, Uesugi U, Tabata R, Miura D, M, Takeuchi M, Matsue K. The safety and efficacy of venetoclax for acute myeloid leukemia in real-world clinical practice. Jap J Clin Oncol. in press.2023 Aug 10.PMID: 37561359
7) Ikeda D, Oura M, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K. Efficacy of darinaparsin for EBV-associated B-cell lymphoma in a heavily treated elderly patient with angioimmunoblastic T-cell lymphoma: a case report. Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2265001. Online ahead of print.PMID: 37794793
8) ＊Onishi Y, Mori T, Yamazaki H, Hiramoto N, Zaimoku Y, Kanaya M, Matsue K, Onizuka M, Aotsuka N, Uchida N, Onodera K, Kanda J, Nakamae H, Yamamoto R, Kuriyama T, Kimura T, Ichinohe T, Atsuta Y; Adult Aplastic Anemia Working Group of the Japanese Society for Transplantation and Cellular Therapy. Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia. Transplant Cell Ther. 2023 Sep 18:S2666-6367(23)01548-8. doi: 10.1016/j.jtct.2023.09.009. Online ahead of print.PMID: 37730121
9)＊ Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Maeda T, Yoshida T, Mori I, Shinozaki T, Iida S.A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Ann Hematol. 2023 Sep 11. doi: 10.1007/s00277-023-05428-7. Online ahead of print.PMID: 37695378
10) Ikeda D, Fukumoto A, Uesugi Y, Tabata R, Miura D, Narita K, Takeuchi M, Watari T, Otsuka Y, Matsue K. Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease. Blood Cancer J. 2023 Sep 5;13(1):133. doi: 10.1038/s41408-023-00897-5.PMID: 37666820
11) Ikeda D, Matsue K. Disseminated nontuberculous mycobacterial infection prior to hematopoietic stem cell transplantation: A case of successful treatment. Transpl Infect Dis. 2023 Oct;25(5):e14121. doi: 10.1111/tid.14121. Epub 2023 Aug 10.PMID: 37561359
12) Fukumoto A, Honma K, Nakaminato S, Kitaura K, Ikeda D, Uesugi Y, Tabata R, Miura D, Narita K, Takeuchi M, Matsue K. Concordance between HokUS-10 Scoring and Transjugular Liver Biopsy for the Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023 Oct;29(10):639.e1-639.e4. doi: 10.1016/j.jtct.2023.06.023. Epub 2023 Jul 7. PMID: 37423340
13) Suma S, Suehara Y, Fujisawa M, Abe Y, Hattori K, Makishima K, Sakamoto T, Sawa A, Bando H, Kaji D, Sugio T, Kato K, Akashi K, Matsue K, Carreras J, Nakamura N, Suzuki A, Suzuki Y, Ito K, Shiiba H, Chiba S, Sakata-Yanagimoto M. Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution. Leukemia. 2023 Nov 27. doi: 10.1038/s41375-023-02093-7. Online ahead of print. PMID: 38012392
14) Uesugi Y, Ikeda D, Fukumoto A, Tabata R, Miura D, Narita K, Takeuchi M, Matsue K. Use of the Second Revision of the International Staging System for prognostic stratification of multiple myeloma patients in real-world clinical practice and the importance of sub-groups, including age.
Haematologica (IF: 9.94; Q1). 2023 Nov 30. doi: 10.3324/haematol.2023.284173. Online ahead of print.PMID: 3803180115) Ikeda D, TTerao T, Oura M, Uehara A, Tabata R, Narita K, Takeuchi M, Machida Y and Matsue K. Analysis of baseline circulating tumour cells integrated with PET/CT findings in transplant-ineligible multiple myeloma. Blood Adv. 2024 Jan 9;8(1):37-46. doi: 10.1182/bloodadvances.2023011890.
- 2022年
-
1) Ikeda D, Tsushima T, Fukumoto A, Kuzume A, Tabata R, Terao T, Miura D, Narita K, Takeuchi M, Honma K, Matsue K. Rapid liver atrophy and refractory ascites due to hepatoportal sclerosis in a patient after haploidentical stem cell transplantation. Leuk Lymphoma. 2022 Jan 12:1-4. doi: 10.1080/10428194.2022.2027400. Online ahead of print.
2) Ikeda D, Matsue K. Non-crystalline light chain proximal tubulopathy without renal Fanconi syndrome in a patient with IgD-λ multiple myeloma. Br J Haematol. 2022 Jan;196(2):261. doi: 10.1111/bjh.17785. Epub 2021 Sep 1.PMID: 34472090 No abstract available.
3) Terao T, Yamashita T, Fukumoto A, Kamura Y, Ikeda D, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Doi M, Umezawa Y, Otsuka Y, Takamatsu H, Matsue K. Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma. Int J Hematol 2022 in press
4) Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, Ikeda D, Fukumoto A, Miura D, Takeuchi M, Doi M, Umezawa Y, Otsuka Y, Takamatsu H, Matsue K. Antibody response to Covid-19 vaccination in patients with lymphoma. Int J Hematol. 2022 Feb 21:1-9. doi: 10.1007/s12185-022-03305-z. Online ahead of print. PMID: 35188650
5) Terao T, Naduka T, Ikeda D, Fukumoto A, Kamura Y, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Matsue K. Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia. Br J Haematol. 2022 Feb 16. doi: 10.1111/bjh.18079. Online ahead of print.PMID: 35172374
6) Kamura Y, Terao T, Akao S, Kono Y, Honma K, Matsue K. Fatal thrombotic microangiopathy with rhabdomyolysis as an initial symptom after the first dose of mRNA-1273 vaccine: A case report.Int J Infect Dis. 2022 Apr;117:322-325. doi: 10.1016/j.ijid.2022.02.031. Epub 2022 Feb 18.PMID: 35189339
7) Tsushima T, Terao T, Narita K, Fukumoto A, Ikeda D, Kamura Y, Kuzume A, Tabata R, Miura D, Takeuchi M, Matsue K. Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation. Int J Hematol. 2022 May;115(5):611-615. doi: 10.1007/s12185-022-03325-9. Epub 2022 Apr 1
8) Nakashima K, Misawa M, Otsuki A, Narita K, Otsuka Y, Matsue K, Aoshima M. Efficacy and Safety of Endobronchial Ultrasonography with a Guide-sheath for Acute Pulmonary Lesions in Patients with Haematological Diseases. Intern Med. 2022;61(5):623-632. doi: 10.2169/internalmedicine.6364-20. Epub 2022 Mar 1.PMID: 35228474
9)* Abe Y, Sakata-Yanagimoto M, Fujisawa M, Miyoshi H, Suehara Y, Hattori K, Kusakabe M, Sakamoto T, Nishikii H, Nguyen TB, Owada Y, Enomoto T, Sawa A, Bando H, Yoshida C, Tabata R, Terao T, Nakayama M, Ohshima K, Usuki K, Oda T, Matsue K, Chiba S. A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling. Nat Cell Biol. 2022 Mar 24. doi: 10.1038/s41556-022-00866-3. Online ahead of print.10) Terao T, Tsushima T, Miura D, Ikeda D, Fukumoto A, Kuzume A, Tabata R, Narita K, Takeuchi M, Matsue K. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.Leuk Lymphoma. 2022 Apr 3:1-9. doi: 10.1080/10428194.2022.2057485. Online ahead of print.PMID: 35373680
11) Matsunami M, Suzuki T, Fukuda J, Terao T, Ukai K, Sugihara S, Toishi T, Nagaoka K, Nakata M, Ohara M, Yashima J, Kuji H, Matsue K. Comparison of antibody response following the second dose of SARS-CoV-2 mRNA vaccine in elderly patients with late-stage chronic kidney disease. Ren Replace Ther. 2022;8(1):13. doi: 10.1186/s41100-022-00402-x. Epub 2022 Apr 5.PMID: 35402003
12) Ikeda D, Terao T, Miura D, Narita K, Fukumoto A, Kuzume A, Kamura Y, Tabata R, Tsushima T, Takeuchi M, Hosoki T, Matsue K. Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib. Front Med (Lausanne). 2022 Mar 25;9:826537. doi: 10.3389/fmed.2022.826537. eCollection 2022.PMID: 35402455
13) Tsushima T, Terao T, Narita K, Fukumoto A, Ikeda D, Kamura Y, Kuzume A, Tabata R, Miura D, Takeuchi M, Matsue K. Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation.
Int J Hematol. 2022 May;115(5):611-615. doi: 10.1007/s12185-022-03325-9. Epub 2022 Apr 15.14)* Matsue K, Sunami K, Matsumoto M, Kuroda J, Sugiura I, Iwasaki H, Chung W, Kuwayama S, Nishio M, Lee K, Iida S. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. Int J Hematol. 2022 Apr 16. doi: 10.1007/s12185-022-03338-4. Online ahead of print.PMID: 3542932
15) Terao T, Matsue K. Progress of modern imaging modalities in multiple myeloma.
Int J Hematol. 2022 May 9. doi: 10.1007/s12185-022-03360-6. Online ahead of print. PMID: 35532876 Review.16) Fukumoto A, Terao T, Kuzume A, Tabata R, Tsushima T, Miura D, keda D, Kamura Y, Narita K, Takeuchi M, Matsue K. Management of lymphoma-associated chylothorax by interventional radiology and chemotherapy: A report of five cases. Int J Hematol. 2022 Jul 10. doi: 10.1007/s12185-022-03397-7. Online ahead of print.PMID: 3581971
17) Matsunami M, Suzuki T, Sugihara S, Toishi T, Nagaoka K, Fukuda J, Ohara M, Takanashi Y, Ochi A, Yashima J, Kuji H, Matsue K. Evaluation of the Correlation Between Responders and Non-Responders to the Second Coronavirus Disease Vaccination In Kidney Transplant Recipients: A Retrospective Single-Center Cohort Study. Transplant Proc. 2022 May 31:S0041-1345(22)00382-7. doi: 10.1016/j.transproceed.2022.05.002. Online ahead of print.PMID: 3586887218) Narita K, Suzuki T, Matsue K. PET/CT imaging of renal intravascular large B-cell lymphoma. Clin Exp Nephrol. 2022 Jul 30. doi: 10.1007/s10157-022-02257-2. Online ahead of print.PMID: 35908129
19)* Fujisawa M, Nguyen TB, Abe Y, Suehara Y, Fukumoto K, Suma S, Makishima K, Kaneko C, Nguyen YTM, Usuki K, Narita K, Matsue K, Nakamura N, Ishikawa S, Miura F, Ito T, Suzuki A, Suzuki Y, Mizuno S, Takahashi S, Chiba S, Sakata-Yanagimoto M. Clonal germinal center B cells function as a niche for T-cell lymphoma.Blood. 2022 Aug 3:blood.2022015451. doi: 10.1182/blood.2022015451. Online ahead of print.PMID: 35921527
20) Matsunami M, Suzuki T, Yashima J, Kuji H, Matsue K. Delayed kinetics of SARS-CoV-2 IgG antibody production in kidney transplant recipients following the third dose of COVID-19 vaccination. Clin Exp Nephrol. 2022 Aug 5:1-2. doi: 10.1007/s10157-022-02261-6. Online ahead of print.PMID: 35931918
21) Tsushima T, Tabata R, Narita K, Honma K, Takeuchi K, Matsue K. Brain toxoplasmosis after HLA haploidentical transplantation for acute myeloid leukemia. EJHaem. 2022 May 16;3(3):1076-1077. doi: 10.1002/jha2.454. eCollection 2022 Aug.PMID: 36051060
22) Terao T, Tsushima T, Ikeda D, Fukumoto A, Kamura Y, Kuzume A, Tabata R, Miura D, Narita K, Takeuchi M, Matsue K. Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL. Leuk Lymphoma. 2022 Sep 16:1-8. doi: 10.1080/10428194.2022.2123239. Online ahead of print.PMID: 36111741
23) Matsunami M, Suzuki T, Sugihara S, Toishi T, Kawaji A, Nagaoka K, Ochi A, Yashima J, Kuji H, Matsue K. Impact of ABO Compatibility/Incompatibility on the Perioperative Anti-SARS-CoV-2 Immunoglobulin G Levels in 2 Preoperatively Vaccinated Patients Undergoing Kidney Transplant: A Case Report. Transplant Proc. 2022 2022 Sep 7;S0041-1345(22)00596-6. doi: 10.1016/j.transproceed.2022.08.046
24) Fukumoto A, Miura D, Matsue K. Successful allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia and preexisting pulmonary nocardiosis. Transplant Infect Dis 2022 Oct 28:e13968. doi: 10.1111/tid.13968. Online ahead of print.
25) Matsunami M, Suzuki T, Sugihara S, Toishi T, Kawaji A, Nagaoka K, Ochi A, Yashima J, Kuji H, Matsue K. Impact of ABO Compatibility/Incompatibility on the Perioperative Anti-SARS-CoV-2 Immunoglobulin G Levels in 2 Preoperatively Vaccinated Patients Undergoing Kidney Transplant: A Case Report. Transplant Proc (IF: 1.07; Q4). 2022 Dec;54(10):2668-2672. doi: 10.1016/j.transproceed.2022.08.046. Epub 2022 Sep 7.PMID: 36207150
26) Ikeda D, Terao T, Fukumoto A, Uesugi Y, Tabata R, Kuzume A, Tsushima T, Miura D, Narita K, Takeuchi M, Yamashita T, Takamatsu H, Matsue K. Antibody status to booster vaccination against SARS-Cov2 virus in patients with haematologic malignancies. Br J Haematol. 2023 Mar;200(5):568-572. doi: 10.1111/bjh.18549. Epub 2022 Nov 7.
27) Tsushima T, Terao T, Narita K, Fukumoto A, Ikeda D, Kamura Y, Kuzume A, Tabata R, Miura D, Masami Takeuchi M, Matsue K. Clinical characteristics and outcomes of cyclin D1-positive AL amyloidosis. Am J Clin Pathol (IF: 2.49; Q3). 2023 Mar 20:aqad013. doi: 10.1093/ajcp/aqad013. Online ahead of print.PMID: 36940250
- 2021年
-
1) Tsushima T, Suzuki T, Terao T, Miura D, Narita K, Takeuchi M, Shimuzu A, Matsue K. Light chain deposition disease involving kidney and liver in a patient with IgD myeloma. BMC Nephrol. 2021 Jan 23;22(1):40. doi: 10.1186/s12882-021-02246-9.PMID: 33485303
2) Terao T, Machida Y, Narita K, Kuzume A, Tabata R, Tsushima T, Miura D, Takeuchi M, Tateishi U, Matsue K. Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma. Eur Radiol. 2021 Jan 26. Doi：10.1007 /s00330-021-07687-2. Online ahead of print
3) Terao T, Matsue K Bone Marrow Necrosis in Acute Monoblastic Leukemia. N Engl J Med. 2021 Feb 18;384(7):650. doi: 10.1056/NEJMicm2026508 PMID: 33596359
4) Terao T, Tsushima T, Fukumoto A, Kuzume A, Miura D, Narita K, Takeuchi M, Matsue K. EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide. Int J Hematol. 2021 Mar 6. doi: 10.1007/s12185-021-03111-z. Online ahead of print
5) Kuzume A, Tabata R, Terao T, Tsushima T, Miura D, Narita K, Takeuchi M, Matsue K.
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure.
Br J Haematol. 2021 Mar 21. doi: 10.1111/bjh.17412. Online ahead of print6) Terao T, Matsuoka K-I, Narita K, Tsushima T, Yuyama S, Kuzume K, Tabata R, Miura D, Takeuchi M, Matsue K. Letermovir administration to prevent cytomegalovirus reactivation is the potential risk of chronic graft-versus-host disease in patients who received haploidentical stem-cell transplantation with post-transplant cyclophosphamide. Front. Oncol., 29 April 2021
7) Yoroidaka T, Narita K, Takamatsu H, Fujisawa M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods. Sci Rep. 2021 May 27;11(1):11218. doi: 10.1038/s41598-021-89761-9
8) Terao T, Machida Y, Hirata K, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Tateishi U, Matsue K. Prognostic Impact of Metabolic Heterogeneity in Patients With Newly Diagnosed Multiple Myeloma Using 18F-FDG PET/CT. Clin Nucl Med. 2021 Oct 1;46(10):790-796. doi: 10.1097/RLU.0000000000003773.PMID: 34172600
9) Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N, Anderson LD Jr, Streetly M, Wilson K, Le HV, Swern AS, Agarwal A, Siegel DS. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021 Jun 18;11(6):116. doi: 10.1038/s41408-021-00507-2.
10) Kitadate A, Terao T, Narita K, Ikeda S, Takahashi Y, Tsushima T, Miura D, Takeuchi M, Takahashi N, Matsue K. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer Sci. 2021 Jul 20. doi: 10.1111/cas.15073. Online ahead of print.
11) Narita K, Miura D, Tsushima T, Terao T, Kuzume A, Tabata R, Takeuchi M, Matsue K. Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria. Sci Rep. 2021 Jul 22;11(1):14956. doi: 10.1038/s41598-021-94191-8.
12) Matsunami M, Suzuki T, Terao T, Kuji H, Matsue K. Immune response to SARS-CoV-2 vaccination among renal replacement therapy patients with CKD: a single-center study. Clin Exp Nephrol. 2021 Nov 8. doi: 10.1007/s10157-021-02156-y. Online ahead of print.
13) Terao T, Machida Y, Tateishi U, Tsushima T, Narita K, Ikeda D, Fukumoto A, Kuzume A, Tabata R, Miura D, Takeuchi M, Matsue K. Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myeloma. Sci Rep. 2021 Dec 14;11(1):23978. doi: 10.1038/s41598-021-03496-1.
- 2020年
-
1)*Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Combined With High-Dose Methotrexate Plus Intrathecal Chemotherapy for Newly Diagnosed Intravascular Large B-cell Lymphoma (PRIMEUR-IVL): A Multicentre, Single-Arm, Phase 2 Trial. Lancet Oncol 2020; 21 (4): 593-602.
2)Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. Br J Haematol. 2020 Apr 6. doi: 10.1111/bjh.16633. Online ahead of print.
3)*Sunami K, Matsue K, Suzuki K, Takezako N, Shinagawa A, Sakurai S, Tamakoshi H, Biyukov T, Peluso T, Richardson P. Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. Cancer Sci. 2020 Apr 16. doi: 10.1111/cas.14415. Online ahead of print.
4)Kobayashi H, Terao T, Tsushima T, Abe Y, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma. Cancer Med. 2020 Apr 20. doi: 10.1002/cam4.3050. Online ahead of print.
5)Terao T, Narita K, Tsushima T, Miura D, Takeuchi M, Matsue K. Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases. Leuk Lymphoma. 2020 Apr 23:1-3. doi: 10.1080/10428194.2020.1742904. Online ahead of print
6)*Suzuki Y, Kohno K, Matsue K, Sakakibara A, Ishikawa E, Shimada S, Shimada K, Mabuchi S, Takahara T, Kato S, Nakamura S, Satou A. PD-L1 (SP142) Expression in Neoplastic Cells Predicts a Poor Prognosis for Patients With Intravascular Large B-cell Lymphoma Treated With Rituximab-Based Multi-Agent Chemotherapy. Cancer Med 2020 May 5. doi: 10.1002/cam4.3104. Online ahead of print
7)Terao, T Tsushima, D Miura, K Narita, M Takeuchi, K Matsue . Social frailty predicts worse outcomes in patients with multiple myeloma: A novelty in an old T eJHaem
8)Kitadate A, Narita K, Fukumoto K, Terao T, Tsushima T, Kobayashi H, Abe Y, Miura D, Takeuchi M, Machida Y, Matsue K. Baseline total lesion glycolysis combined with interim positron emission tomography‐computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma. Cancer Med. 2020 Aug;9(15):5509-5518. doi: 10.1002/cam4.3226. Epub 2020 Jun 18.
9)K Narita, H Kobayashi, T Suzuki, D Ichikawa, K Yamazaki, H Terawaki, Light chain deposition disease in a patient with MYD88 L265P mutation-positive low-grade B-cell … Clinical Lymphoma Myeloma and Leukemia, 2020 Nov;20(11):e805-e808.
10) Trearo T, Tsushima T, Miura D, Narita K, Takeuchi M, Matsue K. Social frailty predicts worse outcomes in patients with multiple myeloma: A novelty in an old approach. eJHaem 2020 ;1(1): 281-285
11)Matsue K, Abe Y, Narita K, Kobayashi H, Kitradate A, Miura D, Takeuchi M, Takeuchi K. Bone marrow infiltration pattern in patients with intravascular large B‐cell lymphoma diagnosed by random skin biopsy. eJHaem 2020 ;1(1): 281-285
12)Kaji D, Ota Y, Sato Y, Nagafuji K, Ueda Y, Okamoto M, Terasaki Y, Tsuyama N, Matsue K, Kinoshita T, Yamamoto G, Taniguchi S, Chiba S, Ohshima K, Izutsu K,. Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood adv. 2020 Sep 22;4(18):4442-4450.
13)Enzan N, Kitadate A, Suzuki H, Yoshioka M, Narita K, Tanaka A, Matsue K. Intravascular large B-cell lymphoma diagnosed by incisional random skin biopsy after failure of diagnosis using punch biopsy: A case report. J Cutan Pathol. 2020 Sep 17. doi: 10.1111/cup.13877. Online ahead of print
14)Terao T, Ashimine H, Tsuyama N, Ikeda D, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Takeuchi K, Matsue K. Development of BCR-ABL1-positive ɤδ T-cell leukemia after treatment for thymoma type B1. Leuk Lymphoma. 2020 Dec 7:1-6
15)Kuzume A, Terao T, Miura D, Takeuchi K, Matsue K. Tiger man sign in sarcoid myopathy.
Rheumatology (Oxford). 2020 Dec 25:keaa833. doi: 10.1093/rheumatology/keaa833. Online ahead of print - 2019年
- 1) Abe Y, Sunami K, Yamashita T, Ueda U, Takamatsu H, Narita K, Kobayashi H, Kitadate A, Takeuchi M, and Matsue K. Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society. Oncotarget 2019;10(5): 595-605.
2) Kobayashi H, Abe Y, Miura M, Narita K, Kitadate A, Takeuchi M, and Matsue K. Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis. Int J Hematol. 2019 Mar;109(3):286-291
3) Kobayashi H, Abe Y, Narita K, Kitadate A, Takeuchi M, and Matsue K. Prevalence and clinical implications of t(11;14) in patients with amyloid light chain-amyloidosis with or without concurrent multiple myeloma. Jpn J Clin Oncol. 2019 Feb 1;49(2):195-198.
4) Enzan N, Kitadate A, Tanaka A, Matsue K. Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: A clinicopathological study of 25 patients. Br J Dermatol. 2019 Jan 4. doi: 10.1111/bjd.17603. [Epub ahead of print]
5) Matsue K, Abe Y, A, Kitadate A, Miura D, Narita K, Kobayashi H, Takeuchi M, Enzan N, Tanaka N, and Takeuchi K. Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood. 2019 Mar 14;133(11): 1257-1259.
6) Abe Y, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K. Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2019 Jan 28. doi: 10.1007/s 00259-019-4275-5. [Epub ahead of print]
7) Abe Y, Kitadate A, Usui Y, Narita K, Kobayashi H, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K. Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-cell Lymphoma. Clin Nucl Med. 2019 May;44(5):e336-e341.
8) Abe Y, Kobayashi T, Usui Y, Narita K, Kobayashi H, Kitadate A, Miura M, Takeuchi M, and Matsue K. N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma. Oncotarget. 2019 Feb 1;10(10):1160-1170.
9) *Takamatsu H, Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T, Murata R, Ueda M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol. 2019 Apr;109(4):505. doi: 10.1007/s12185-019-02621-1
10) Abe Y, Ikeda S, Kitadate A,, Narita K, Kobayashi H, Miura D, Takeuchi M, O’uchi E, O’uchi T, Matsue K. Low hexokinase-2 expression-associated false-negative ¹⁸F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019 46(6):1345-1350.
11) Kobayashi H, Tsushima T, Terao T, Abe Y, Miura M, Narita K, Kitadate A, Takeuchi M, Matsue K. Evaluation [A1] of the safety and efficacy of daratumumab outside of clinical trials. Int J Hematol. 2019 Apr 8. doi: 10.1007/s12185-019-02648-4. [Epub ahead of print]
12) Kitadate A, Kobayashi K, Abe A, Kentaro K, Miura D, Takeuchi M, and Matsue M. Pretreatment CD38-positive regulatory T-cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma. Haematologica. 2019 Apr 19. pii: haematol.2019.219683. doi: 10.3324/haematol. 2019.219683. [Epub ahead of print]
13) Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Ouchi E, Ouchi T, Matsue K. Medullary abnormalities in the appendicular skeletons detected by ¹⁸F-FDG PET/CT predict an unfavorable prognosis in newly diagnosed multiple myeloma patients with established high-risk factors. AJR Am J Roentgenol. 2019 Jun 19:1-7. doi: 10.2214/ AJR.19.21283. [Epub ahead of print]
14) Abe Y, Kobayashi T, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, and Matsue K. Left ventricular diastolic function assessment using echocardiography for predicting carfilzomib-induced cardiovascular events in relapsed/refractory myeloma. Blood Advances. 2019 Jun 11;3(11):1725-1728. doi: 10.1182/bloodadvances. 2019000247.
15) Matsue K, Abe Y, Narita K, Kobayashi H, KitadateA, Takeuchi M, Miura D, Takeuchi K. Diagnosis of intravascular large B-cell lymphoma: Novel insights into clinincopathologic features from 42 patients at a single institution over 20-years. Brit J Haematol. In press.
16) Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Daisuke Miura, Masami Takeuchi, and Kosei Matsue. High frequency of false-positive serum galactomannan tests among older subjects and the association with elevated serum immunoglobulin G levels. Mycoses 2019 Jun 5. doi: 10.1111/myc.12951. [Epub ahead of print]
17) Narita K, Kobayashi H, Kitadate A, Abe Y, Miura D, Takeuchi M, Matsue K. Neurolymphomatosis of the sciatic and tibial nerves as an initial presentation of lung diffuse large B cell lymphoma detected by positron emission tomography/computed tomography. Int J Hematol. 2019 Jul 15. doi: 10.1007/s12185-019-02705-y. [Epub ahead of print]
18) Terao T, Matsue K. Osteosclerotic myeloma without features of POEMS syndrome. Int J Hematol. 2019 Aug 12. doi: 10.1007/s12185-019-02718-7. [Epub ahead of print]
19)* Takahashi T, Usuki K, Matsue K, Ohno H, Sakura T, Imanaka R, Murakami M, Ohwada S, Takagi T, Sakajiri S. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. Int J Hematol. 2019 Dec;110(6):665-674. doi: 10.1007/s12185-019-02727-6. Epub 2019 Aug 31.
20)* Nakamura A, Ohwada C, Takeuchi M, Takeda Y, Tsukamoto S, Mimura N, Nagisa OH, Sugita Y, Tanaka H, Wakita H, Aotsuka N, Matsue K, Yokote K, Ohara O, Nakaseko C, Sakaida E. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS One. 2019 Sep 4;14(9):e0221941.
21) Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Matsue K. 18F-FDG PET/CT-Guided Diagnosis and Evaluation of Treatment Response to Cyclosporine A in Maldistributed Subcutaneous Panniculitis-like T-Cell Lymphoma Without Typical Skin Rash. Clin Nucl Med. 2020 Feb;45(2):e69-e71.
22) Enzan N, Kitadate A, Yoshioka M, Narita K, Tanaka A, Matsue K. Cutaneous involvement of diffuse large B-cell lymphoma incidentally diagnosed based on random skin biopsy of normal-appearing skin. Eur J Dermatol. 2019 Dec 1;29(6):666-667
23) *Taneda S, Honda K, Horita S, Matsue K, Usui Y, Mitobe M, Ogura S, Nitta K, Oda H. An Unusual Case of Lysosomal Paraprotein Accumulation in Glomerular Endothelial Cells. Kidney Int Rep. 2019 Oct 1;5(1):109-115.
診療関連トピックス
対象疾患
血液・腫瘍内科では主として白血病、リンパ腫、骨髄腫、MDS などの造血器悪性腫瘍を中心に診療が行われているが、小細胞性肺ガン、肉腫等の強力な化学療法によって効果が得られる 固形腫瘍、その他自己免疫性溶血性貧血、ITP などの患者さまについても積極的な化学療法が 行われている。
診療実績
入院延べ患者数 27,445名
（2022年度実績）
- 疾患別症例数（2022年度実績）
-
入院患者数 ホジキン病 9 ろ<濾>胞性［結節性］非ホジキンリンパ腫 38 びまん性非ホジキンリンパ腫 288 末梢性及び皮膚Ｔ細胞リンパ腫 29 非ホジキンリンパ腫のその他及び詳細不明の型 24 T/NK細胞リンパ腫のその他の明示された型 30 悪性免疫増殖性疾患 10 多発性骨髄腫及び悪性形質細胞性新生物 136 リンパ性白血病 88 骨髄性白血病 164 単球性白血病 3 骨髄異形成症候群 75 リンパ組織，造血組織及び関連組織の性状不詳又は不明のその他の新生物 11 鉄欠乏性貧血 1 ビタミンＢ12欠乏性貧血 2 葉酸欠乏性貧血 1 後天性溶血性貧血 2 その他の無形成性貧血 18 その他の貧血 4 遺伝性第Ⅷ因子欠乏症 1 紫斑病及びその他の出血性病態 26 白血球のその他の障害 3 主として抗体欠乏を伴う免疫不全症 1 その他の免疫機構の障害，他に分類されないもの 2 アミロイドーシス<アミロイド症> 9 移植臓器及び組織の不全及び拒絶反応 6 臓器及び組織の提供者<ドナー> 15 コロナウイルス感染症2019 29 その他 46 合計 1,071
